IN SILICO ANALYSIS OF SMALL INTERFERING RNA TARGETING THE NUCLEOPROTEIN GENE OF INFLUENZA VIRUSES
Main Article Content
Abstract
Small interfering RNA (siRNA) is a promising therapeutic against viral infection, includ-ing Influenza viruses. However, the Influenza viruses have massive variants with high mutation rates. Therefore, the siRNAs could be futile against newly emerging viruses. Thus, this study aimed to analyze siRNAs targeting the nucleoprotein gene of Influen-za viruses. Using bioinformatic analyses, the siRNAs were simulated against 5 sub-types of Influenza viruses, including H1N1, H3N2, H5N1, H7N9, and H9N2. Bioinfor-matic tools for the folding structure of messenger RNA were utilized to select effective siRNA. As a result, 32 siRNA sequences targeting the nucleoprotein gene were identi-fied. The precision medicine concept seems applied to the siRNA treatment for the In-fluenza virus since each siRNA is effective in its respective virus target. Based on the nucleotide mismatch parameter, most siRNA does not have coverage for the multiple infections of all five subtypes of Influenza viruses, except for NP1089 and NP1496. Later, the secondary and tertiary structure analysis of messenger RNA demonstrated that siRNA has different circumstances in its RNA target position. Therefore, siRNA mapping based on the RNA folding structure approach provides a tool for selecting more effective sequences against Influenza virus infection. Both siRNA NP1089 and NP1496 were predicted to have similar effectivity in knocking down Influenza virus in-fection. Moreover, the cocktail application of siRNA treatment may be effective as an alternative strategy in matching co-infection of multiple Influenza virus subtypes.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
a). Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Attribution-NonCommercial-ShareAlike 4.0 International that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b). Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c). Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
References
Ahn I, Kang CS, Han J (2023) Where should siRNAs go: applicable organs for siRNA drugs. Exp Mol Med 55:1283–1292. doi: https://doi.org/10.1038/s12276-023-00998-y
Behera P, Nagarajan S, Murugkar HV, Kalaiyarasu S, Prakash A, Gothalwal R, Dubey C, Kulkarni DD, Tosh C (2015) siRNAs targeting PB2 and NP genes potentially inhibit replication of highly pathogenic H5N1 avian Influ-enza virus. J Biosci 40:233-240. doi: https://doi.org/10.1007/s12038-015-9524-6
Bouvier NM, Palese P (2008) The biology of Influenza viruses. Vaccine 26:D49-D53. doi: https://doi.org/10.1016/j.vaccine.2008.07.039
Brodskaia AV, Timin AS, Gorshkov AN, Muslimov AR, Bondarenko AB, Tara-kanchikova YV, Zabrodskaya YA, Baranovskaya IL, Il'inskaja EV, Sak-henberg EI, Sukhorukov GB, Vasin AV (2018) Inhibition of Influenza A vi-rus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid micro-carriers. Antiviral Res 158:147-160. doi: https://doi.org/10.1016/j.antiviral.2018.08.003
Bui CM, Chughtai AA, Adam DC, MacIntyre CR (2017) An overview of the epide-miology and emergence of Influenza A infection in humans over time. Arch Public Health 75:15. doi: https://doi.org/10.1186/s13690-017-0182-z
Chan CY, Carmack CS, Long DD, Mali-yekkel A, Shao Y, Roninson IB, Ding Y (2003) A structural interpretation of the effect of GC-content on efficiency of RNA interference. BMC Bioinf 10:S33. doi: https://doi.org/10.1186/1471-2105-10-S1-S33
Chowdhury UF, Shohan MUS, Hoque KI, Beg MA, Siam MKS, Moni MA (2021) A computational approach to design potential siRNA molecules as a pro-spective tool for silencing nucleocap-sid phosphoprotein and surface gly-coprotein gene of SARS-CoV-2. Ge-nomics 113(1): 331-343. doi: https://doi.org/10.1016/j.ygeno.2020.12.021
Dong Y, Siegwart DJ, Anderson DG (2019) Strategies, design, and chemistry in siRNA delivery systems. Adv Drug Deliv Rev 144:133-147. doi: https://doi.org/10.1016/j.addr.2019.05.004
Draz MS, Fang BA, Zhang P, Hu Z, Gu S, Weng KC, Gray JW, Chen FF (2014) Nanoparticle-mediated systemic de-livery of siRNA for treatment of can-cers and viral infections. Theranostics 4:872-892. doi: https://www.thno.org/v04p0872.htm
Earhart KC, Elsayed NM, Saad MD, Guba-reva LV, Nayel A, Deyde VM, Abdel-sattar A, Abdelghani AS, Boynton BR, Mansour MM, Essmat HM, Klimov A, Shuck-Lee D, Monteville MR, Tjaden JA (2009) Oseltamivir resistance mu-tation N294S in human influenza A(H5N1) virus in Egypt. J Infec Public Health 2:74-80. doi: https://doi.org/10.1016/j.jiph.2009.04.004
Ge Q, McManus MT, Nguyen T, Shen CH, Sharp PA, Eisen HN, Chen J (2003) RNA interference of Influenza virus production by directly targeting mRNA for degradation and indirectly inhibit-ing all viral RNA transcription. Proc Natl Acad Sci USA 100:2718-2723. doi: https://doi.org/10.1073/pnas.0437841100
Ge Q, Filip L, Bai A, Nguyen T, Eisen H, Chen J (2004) Inhibition of Influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA 101:8676-8681. doi: https://doi.org/10.1073/pnas.0402486101
Guo F, Li Y, Yu W, Fu Y, Zhang J, Cao H (2024a) Recent progress of small in-terfering RNA delivery on the market and clinical stage. Mol Pharmaceutics 21:2081-2096. doi: https://doi.org/10.1021/acs.molpharmaceut.3c01158
Guo S, Zhang M, Huang Y (2024b) Three ‘E’ challenges for siRNA drug devel-opment. Trends Mol Med 30(1):13-24. doi: https://doi.org/10.1016/j.molmed.2023.10.005
Harrington WN, Kackos CM, Webby RJ (2021) The evolution and future of In-fluenza pandemic preparedness. Exp Mol Med 53:737-749. doi: https://doi.org/10.1038/s12276-021-00603-0
Hartawan R, Pujianto DA, Dharmayanti NLPI, Soebandrio A (2022) Improving siRNA design targeting nucleoprotein gene as antiviral against the Indone-sian H5N1 virus. J Vet Sci 23:e24. doi: https://doi.org/10.4142/jvs.21174
Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, Liang XJ (2020) Therapeutic siRNA: state of the art. Sig Transduct Target Ther 5:101. doi: https://doi.org/10.1038/s41392-020-0207-x
Huang DT, Lu CY, Shao PL, Chang LY, Wang JY, Chang YH, Lai MJ, Chi YH, Huang LM (2017) In vivo inhibition of Influenza A virus replication by RNA interference targeting the PB2 subunit via intratracheal delivery. PLOS ONE 12:e0174523. doi: https://doi.org/10.1371/journal.pone.0174523
Jadhav V, Vaishnaw A, Fitzgerald K, Maier MA (2024) RNA interference in the era of nucleic acid therapeutics. Nat Biotechnol 42:394-405. doi: https://doi.org/10.1038/s41587-023-02105-y
Kang H, Ga YJ, Kim SH, Cho YH, Kim JW, Kim C, Yeh JY (2023) Small interfer-ing RNA (siRNA)-based therapeutic applications against viruses: princi-ples, potential, and challenges. J Bi-omedical Sci 30:88. doi: https://doi.org/10.1186/s12929-023-00981-9
Lam JKW, Chow MY, Zhang Y, Leung SW (2015) siRNA versus miRNA as ther-apeutics for gene silencing. Mol Ther Nucleic Acids 4:e252. doi: https://doi.org/10.1038/mtna.2015.23
Lorenz R, Bernhart SH, Honer Zu Sieder-dissen C., Tafer H, Flamm C, Stadler PF, Hofacker IL (2011) ViennaRNA Package 2.0. Algorithms Mol Bio. 6:26. doi: https://doi.org/10.1186/1748-7188-6-26
Naito Y, Yoshimura J, Morishita S, Ui-Tei K (2009) siDirect 2.0: updated software for designing functional siRNA with reduced seed-dependent off-target ef-fect. BMC Bioinf 10:392. doi: https://doi.org/10.1186/1471-2105-10-392
Neary MT, Mulder LM, Kowalski PS, MacLoughlin R, Crean AM, Ryan KB (2024) Nebulised delivery of RNA formulations to the lungs: From aero-sol to cytosol. J Control Release 366:812-833. doi: https://doi.org/10.1016/j.jconrel.2023.12.012
Okomo-Adhiambo M, Fry AM, Su S, Ngu-yen HT, Elal AA, Negron E, Hand J, Garten RJ, Barnes J, Xiyan X, Vil-lanueva JM, Gubareva LV, 2013-14 US Influenza Antiviral Working Group (2015) Oseltamivir-resistant Influenza A(H1N1)pdm09 viruses, United States, 2013-14. Emerg Infec Dis 21:136-141. doi: http://dx.doi.org/10.3201/eid2101.141006
Piasecka J, Lenartowicz E, Soszynska-Jozwiak M, Szutkowska B, Kierzek R, Kierzek E (2020) RNA secondary structure motifs of the Influenza A vi-rus as targets for siRNA-mediated RNA interference. Mol Ther Nucleic Acids. 19:627-642. doi: https://doi.org/10.1016/j.omtn.2019.12.018
Qureshi A, Tantray VG, Kirmani AR, Ahangar AG (2018) A review on cur-rent status of antiviral siRNA. Rev Med Virol 28:e1976. doi: https://doi.org/10.1002/rmv.1976
Ranasinghe P, Addison ML, Dear JW, Webb DJ (2022) Small interfering RNA: Discovery, pharmacology and clinical development-An introductory review. Br J Pharmacol 180(21):2697-2720. doi: https://doi.org/10.1111/bph.15972
Szabat M, Lorent D, Czapik T, To-maszewska M, Kierzek E, Kierzek R (2020) RNA secondary structure as a first step for rational design of the oli-gonucleotides towards inhibition of In-fluenza A virus replication. Pathogens 9(11):925. doi: https://doi.org/10.3390/pathogens9110925
Sarzynska J, Popenda M, Antczak M, Szachniuk M (2023) RNA tertiary structure prediction using RNAComposer in CASP15. PRO-TEINS: Struct Funct Bioinf 91:1790-1799. doi: https://doi.org/10.1002/prot.26578
Soszynska-Jozwiak M, Michalak P, Moss N, Kierzek R, Kierzek E (2015) A con-served secondary structural element in the coding region of the Influenza A virus nucleoprotein (NP) mRNA is im-portant for the regulation of viral pro-liferation. PLOS ONE. 10:e0141132. doi: https://doi.org/10.1371/journal.pone.0141132
Szczesniak I, Baliga-Gil A, Jarmolowicz A, Soszynska-Jozwiak M, Kierzek E (2023) Structural and functional RNA motifs of SARS-CoV-2 and Influenza A virus as a target of viral inhibitors. Int J Mol Sci 24:1232. doi: https://doi.org/10.3390/ijms24021232
Thangamani L, Balasubramanian B, Nata-rajan J, Pushparaj K, Easwaran M, Meyyazhagan A, Piramanayagam S (2021) GalNAc-siRNA conjugates: Prospective tools on the frontier of an-ti-viral therapeutics. Pharmacol Res 173:105864. doi: https://doi.org/10.1016/j.phrs.2021.105864
Timin AS, Muslimov AR, Petrova AV, Lepik KV, Okilova, MV, Vasin AV, Afanasyev BV, Sukhorukov GB (2012) Hybrid inorganic-organic cap-sules for efficient intracellular delivery of novel siRNAs against Influenza A (H1N1) virus infection. Sci Rep 7:102. doi: https://doi.org/10.1038/s41598-017-00200-0
Tompkins SM, Lo CY, Tumpey TM, Epstein SL (2004) Protection against lethal In-fluenza virus challenge by RNA inter-ference in vivo. Proc Natl Acad Sci USA 101:8682-8686. doi: https://doi.org/10.1073/pnas.0402630101
Villa R, Renzi S, Dotti S, Lucchini F (2023) siRNAs pools generated in Escherich-ia coli exhibit strong RNA-interference activity against Influenza virus ge-nomic sequences. Virology. 579:38-45. doi: https://doi.org/10.1016/j.virol.2022.12.013
Wang Y, Jin B, Li B, Luo Y, Ma M, Chen Y, Liu H, Xie H, Yang T, Zhao X, Ding P
(2022) Cell-free protein synthesis of influenza virus hemagglutinin HA2-integrated virosomes for siRNA deliv-ery. Int J Pharm 623:121890. doi: https://doi.org/10.1016/j.ijpharm.2022.121890
Zhiqiang W, Yaowu Y, Fan Y, Jian Y, Yongfeng H, Lina Z, Jianwei W, Qi J (2010) Effective siRNAs inhibit the replication of novel Influenza A (H1N1) virus. Antivir Res 85:59-561. doi: https://doi.org/10.1016/j.antiviral.2009.12.010
Zhou H, Jin M, Yu Z, Xu X, Peng Y, Wu H, Liu J, Liu H, Cao S, Chen H (2007) Effective small interfering RNAs tar-geting matrix and nucleocapsid pro-tein gene inhibit Influenza A virus rep-lication in cells and mice. Antivir Res 76:186-193. doi: https://doi.org/10.1038/s41586-020-2223-y
Zhou Z, He H, Wu Y, Duan M (2008) RNA interference of avian influenza virus H5N1 by inhibiting viral mRNA with siRNA expression plasmids. J Bio-technol 135:140-144. doi: https://doi.org/10.1016/j.jbiotec.2008.03.007